Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01585701
Other study ID # CRUKD/12/001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2012
Est. completion date January 10, 2018

Study information

Verified date July 2018
Source Cancer Research UK
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this first clinical study of the noval multiple AGC kinase inhibitor, AT13148, is to identify the recommended dose for future studies in cancer patients by exploring the safety and maximum tolerated dose and biological effects in patients with advanced solid tumours.


Description:

AT13148 is a new drug which looks promising in laboratory studies. We now wish to find out if it will be useful in treating patients with cancer. AT13148 is a type of drug called a protein kinase inhibitor. It blocks several different chemical messengers (enzymes) called AGC kinase proteins. These chemical messengers are part of the signaling process within cells which can make cells produce chemicals that trigger and control cell growth and cell death. In some types of cancer these chemical messengers are 'switched on' or 'switched off' permanently due to changes in the genes of cells called "gene mutations" leading to uncontrolled cancer cell growth. AT13148 targets multiple protein kinases from three families of kinases unlike many of the other protein kinase inhibitors currently being tested which target just one or two kinases. This may mean that it will work better and in a wider group of cancer patients. Patients will not be selected to take part based on having these gene mutations for this first trial because we want to learn more about which mutations are most important but this would be the hope for future trials. The patient population anticipated to benefit from this drug includes certain types of breast, prostate and ovarian cancer which more commonly have these gene mutations.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date January 10, 2018
Est. primary completion date January 10, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient. Paraffin-embedded tumour tissue must be available for genetic mutation status testing.

2. Life expectancy of at least 12 weeks

3. World Health Organisation (WHO) performance status of 0, 1 or 2

4. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within 7 days before their first dose of AT13148 taken between Day -7 to -4.

Laboratory Test Value required

Haemoglobin (Hb) = 9.0 g/dL

Absolute neutrophil count = 1.5 x 10^9 /L

Platelet count = 100 x 10^9/L

Fasting glucose = 7 mmol/L

Either:

Serum bilirubin = 1.5 x upper limit of normal (ULN)

Or:

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x (ULN) unless raised due to tumour in which case up to 5 x ULN is permissible

Either:

Calculated creatinine clearance = 50 mL/min

Or:

Isotope clearance measurement = 50mL/min (uncorrected)

5. Adequate lung function indicated by a resting oxygen saturation level (on air) = 94%, a CO-transfer factor > 60%

6. 18 years or over

7. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up

Exclusion Criteria:

1. Radiotherapy (except for palliative reasons), endocrine therapy (except luteinizing hormone releasing hormone (LHRH) agonists for prostate cancer), immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C) and 4 weeks for investigational medicinal products) before treatment.

2. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the Drug Development Office (DDO) should not exclude the patient.

3. Symptomatic brain metastases (if present they must have been stable for > 3 months).

4. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have a intra-uterine device and condom, diaphragm with spermicidal gel and condom) during the study and for six months afterwards are considered eligible.

5. Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using one form of highly effective contraception [condom plus spermicide] during the study and for six months afterwards). Men with pregnant or lactating partners should be advised to use barrier method contraception (e.g. condom plus spermicidal gel) to prevent exposure to the foetus or neonate.

6. Major thoracic or abdominal surgery from which the patient has not yet recovered.

7. At high medical risk because of non-malignant systemic disease including active uncontrolled infection.

8. Known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).

9. History of auto-immune disease or known allergy to peanuts.

10. Concurrent hypotension defined as a baseline supine blood pressure (BP) systolic < 90 mmHg.

11. Patients receiving anti-hypertensive treatment or treatment with beta- blockers or rate-limiting calcium agents. A washout period of 5 x half- life of the drug should be applied following withdrawal of any of these treatments.

12. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior history of cardiac arrhythmia. Coronary angioplasty or stenting in the previous 12 months.

13. Patients with a known left ventricular ejection fraction (LVEF) < 50%. A multi-gated acquisition (MUGA) scan or echocardiogram (ECHO) must be performed in all patients.

14. Concurrent diabetes requiring treatment (diet-controlled diabetes would be acceptable).

15. Prior bone marrow transplant or have had extensive radiotherapy to greater than 25% of bone marrow within eight weeks.

16. A history of or underlying interstitial lung disease.

17. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical study.

18. Is a participant or plans to participate in another interventional clinical study whilst taking part in this study. Participation in an observational study would be acceptable.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
AT13148
Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.

Locations

Country Name City State
United Kingdom Royal Marsden Hospital, Institute of Cancer Research Sutton Surrey

Sponsors (1)

Lead Sponsor Collaborator
Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determining a dose at which no more than one patient out of up to six patients at the same dose level experience a highly probably or probably drug-related dose limiting toxicity (DLT).
Primary Determining causality of each adverse event Adverse Event to AT13148 and grading severity according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.02.
Secondary Determining the correlation between pharmacokinetic studies and toxicity and/or efficacy.
Secondary Any response (stable disease, partial response or complete response) in any of the patients as determined by the Response Evaluation Criteria in Solid Tumours RECIST) criteria version 1.1.criteria version 1.1.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05514132 - A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours Phase 1
Terminated NCT04949425 - A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Phase 1
Not yet recruiting NCT05537051 - A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours Phase 1
Completed NCT02579226 - A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT01668550 - A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours Phase 1
Completed NCT01058538 - A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02588105 - Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Phase 1
Recruiting NCT03852823 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1
Not yet recruiting NCT06380816 - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer Phase 1/Phase 2
Completed NCT03101839 - Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Phase 1
Completed NCT03150368 - Extended Use of ModraDoc006/r Phase 1
Active, not recruiting NCT02389842 - PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib Phase 1
Terminated NCT01581060 - Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours Phase 1/Phase 2
Terminated NCT04959266 - A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib Phase 1
Completed NCT04462952 - Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours Phase 1
Active, not recruiting NCT03518606 - Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02430311 - The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. Phase 1
Terminated NCT01859351 - Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours Phase 1
Completed NCT01163903 - Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours Phase 1
Recruiting NCT05804526 - A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours Phase 1/Phase 2